Skip to main content
. 2023 May 19;11:e15357. doi: 10.7717/peerj.15357

Table 1. Baseline characteristics of BMs patients who received SRS or SRT.

Shows the frequency and proportion of baseline characteristics by SRS and SRT.

Variable SRS N (%)
5,423 (77.9)
SRT N (%)
1,538 (22.1)
Total
6,961
Age at diagnosis, Median (range) 65.0 (21–90) 65.0 (24–90) 65.0 (21–90)
Sex Male 2,733 (50.4) 786 (51.1) 3,519 (50.6)
Female 2,690 (49.6) 752 (48.9) 3,442 (49.5)
Race White 4,580 (85.2) 1,307 (85.8) 5,887 (85.4)
Black 588 (10.9) 155 (10.2) 743 (10.8)
Other 205 (3.8) 62 (4.1) 267 (3.9)
Unknown 50 14 64
Education
NHSD
>=13% 2,178 (40.2) 652 (42.5) 2,830 (40.7)
(No High School Degree) <13% 3,235 (49.8) 881 (57.5) 4,116 (59.3)
Unknown 10 5 15
Income >=$35,000 3,310 (61.2) 944 (61.6) 4,254 (61.3)
<35,000 2,101 (38.8) 589 (38.4) 2,690 (38.7)
Unknown 12 5 17
Place of Living Urban 5,175 (98.1) 1,477 (98.8) 6,652 (98.3)
Rural 98 (1.9) 18 (1.2) 116 (1.7)
Unknown 150 43 193
Hospital Type Academic 2,501 (46.8) 699 (46.1) 3,200 (46.7)
Community 2,843 (53.2) 817 (53.9) 3,660 (53.4)
Unknown 79 22 101
Insurance Status Yes 5,197 (96.9) 1,477 (97.2) 6,674 (97.0)
No 166 (3.1) 43 (2.8) 209 (3.0)
Unknown 60 16 78
Charlson/Deyo Score 0 3,686 (68.0) 976 (63.5) 4,662 (67.0)
1 1,209 (22.3) 380 (24.7) 1,589 (22.8)
>=2 528 (9.7) 182 (11.8) 710 (10.2)
Chemotherapy Yes 3,979 (73.4) 1,045 (68.0) 5,024 (72.2)
No 1,444 (26.6) 493 (32.1) 1,937 (27.8)
Immunotherapy Yes 406 (7.5) 123 (8.0) 529 (7.6)
No 5,017 (92.5) 1,415 (92.0) 6,432 (92.4)
Cancer Type Breast 127 (2.3) 44 (2.9) 171 (2.5)
NSCLC 4,407 (81.3) 1,188 (77.2) 5,595 (80.4)
SCLC 162 (3.0) 42 (2.7) 204 (2.9)
Other Lung 159 (2.9) 63 (4.1) 222 (3.2)
Melanoma 320 (5.9) 120 (8.4) 449 (6.5)
CRC 45 (0.8) 22 (1.4) 67 (1.0)
Renal Cell 203 (3.7) 50 (3.3) 253 (3.6)
Year of Diagnosis 2010–2013 2,931 (54.1) 709 (46.1) 3,640 (52.3)
2014–2015 2,492 (46.0) 829 (53.9) 3,321 (47.7)